+Follow
78887480
No personal profile
4
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
78887480
2022-02-03
Like pls thanks
PayPal, Block, other fintech stocks return to earth after COVID boost
78887480
2022-02-06
Nice
Big Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash
78887480
2022-02-03
Like pls thanks
2 Biotech Stocks That Could Make You Richer
78887480
2022-02-03
Good
MetLife Q4 Profit Beats View
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":4106832071804060,"uuid":"4106832071804060","gmtCreate":1643729002992,"gmtModify":1643729002992,"name":"78887480","pinyin":"78887480","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":1,"fanSize":0,"headSize":4,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.06.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9098877231,"gmtCreate":1644109434122,"gmtModify":1676533890164,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098877231","repostId":"2209346488","repostType":4,"repost":{"id":"2209346488","pubTimestamp":1644030901,"share":"https://www.laohu8.com/m/news/2209346488?lang=&edition=full","pubTime":"2022-02-05 11:15","market":"us","language":"en","title":"Big Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2209346488","media":"Bloomberg","summary":"This week was one for the record books for big tech, in ways both good and historically bad.Results ","content":"<html><head></head><body><p>This week was one for the record books for big tech, in ways both good and historically bad.</p><p>Results from a trio of Wall Street’s most widely followed names spurred huge weekly moves, with hundreds of billions of dollars getting created or evaporated. For Alphabet Inc. and Amazon.com Inc., strong reports underlined their growth prospects, spurring rallies that led to their biggest one-week percentage gains in months. For <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, the Facebook parent that had the single-worst day in Wall Street history by one metric, it was a different story.</p><p>Alphabet rose 7.5% for the week, its best such performance since October. Earlier this week, it reported results that beat expectations, help by a robust performance in its advertising business. The week’s advance added $122.5 billion to its market valuation, bringing it close to the $2 trillion threshold. It rose 0.1% on Friday.</p><p>Amazon rose 9.5% for the week, its biggest one-week gain since July 2020. The bulk of the week’s advance came on Friday, when shares surged nearly 14% on the back of a report that also sailed past expectations. Friday’s move was the biggest percentage gain for the stock since April 2015, and the nearly $191 billion it added in market value was a record one-day value gain for the U.S. market.</p><p>On the other end of the scale, Meta fell 21% over the week, its biggest one-week drop on record. The collapse came after it gave a weak revenue forecast amid stagnating user growth and increasing competition from TikTok. Shares suffered their biggest drop ever on Thursday, resulting in the biggest one-day wipeout of market value for any U.S. company in history. The stock fell 0.3% on Friday.</p><p>Overall, the tech-heavy Nasdaq 100 Index rose 1.7% for the week, its second straight weekly gain. Last week it was supported by strong reports from other mega-cap stocks, including Apple Inc. and Microsoft.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 11:15 GMT+8 <a href=https://finance.yahoo.com/news/big-tech-week-featured-alphabet-212244501.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This week was one for the record books for big tech, in ways both good and historically bad.Results from a trio of Wall Street’s most widely followed names spurred huge weekly moves, with hundreds of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/big-tech-week-featured-alphabet-212244501.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","GOOG":"谷歌","BK4525":"远程办公概念","BK4566":"资本集团","AMZN":"亚马逊","BK4535":"淡马锡持仓","BK4524":"宅经济概念","BK4508":"社交媒体","BK4527":"明星科技股","BK4538":"云计算","BK4559":"巴菲特持仓","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","AAPL":"苹果","BK4561":"索罗斯持仓","BK4548":"巴美列捷福持仓","MSFT":"微软","GOOGL":"谷歌A"},"source_url":"https://finance.yahoo.com/news/big-tech-week-featured-alphabet-212244501.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2209346488","content_text":"This week was one for the record books for big tech, in ways both good and historically bad.Results from a trio of Wall Street’s most widely followed names spurred huge weekly moves, with hundreds of billions of dollars getting created or evaporated. For Alphabet Inc. and Amazon.com Inc., strong reports underlined their growth prospects, spurring rallies that led to their biggest one-week percentage gains in months. For Meta Platforms, the Facebook parent that had the single-worst day in Wall Street history by one metric, it was a different story.Alphabet rose 7.5% for the week, its best such performance since October. Earlier this week, it reported results that beat expectations, help by a robust performance in its advertising business. The week’s advance added $122.5 billion to its market valuation, bringing it close to the $2 trillion threshold. It rose 0.1% on Friday.Amazon rose 9.5% for the week, its biggest one-week gain since July 2020. The bulk of the week’s advance came on Friday, when shares surged nearly 14% on the back of a report that also sailed past expectations. Friday’s move was the biggest percentage gain for the stock since April 2015, and the nearly $191 billion it added in market value was a record one-day value gain for the U.S. market.On the other end of the scale, Meta fell 21% over the week, its biggest one-week drop on record. The collapse came after it gave a weak revenue forecast amid stagnating user growth and increasing competition from TikTok. Shares suffered their biggest drop ever on Thursday, resulting in the biggest one-day wipeout of market value for any U.S. company in history. The stock fell 0.3% on Friday.Overall, the tech-heavy Nasdaq 100 Index rose 1.7% for the week, its second straight weekly gain. Last week it was supported by strong reports from other mega-cap stocks, including Apple Inc. and Microsoft.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091280276,"gmtCreate":1643872269422,"gmtModify":1676533866453,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls thanks","listText":"Like pls thanks","text":"Like pls thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280276","repostId":"1196109622","repostType":4,"repost":{"id":"1196109622","pubTimestamp":1643852105,"share":"https://www.laohu8.com/m/news/1196109622?lang=&edition=full","pubTime":"2022-02-03 09:35","market":"us","language":"en","title":"2 Biotech Stocks That Could Make You Richer","url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","media":"Motley Fool","summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","content":"<html><head></head><body><p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.</p><p>Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a> and <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a>. Here's why.</p><p>1. <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a></p><p>To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.</p><p>On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.</p><p>However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called<b>2Seventy Bio</b>.</p><p>Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.</p><p>There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.</p><p>The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).</p><p>ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.</p><p>Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.</p><p>However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.</p><p>2. <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a></p><p>Exelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.</p><p>Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.</p><p>First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.</p><p>Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.</p><p>The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.</p><p>Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8 <a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","BLUE":"bluebird bio Inc."},"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196109622","content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091280665,"gmtCreate":1643872246305,"gmtModify":1676533866452,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls thanks","listText":"Like pls thanks","text":"Like pls thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280665","repostId":"2208572369","repostType":4,"repost":{"id":"2208572369","pubTimestamp":1643867517,"share":"https://www.laohu8.com/m/news/2208572369?lang=&edition=full","pubTime":"2022-02-03 13:51","market":"us","language":"en","title":"PayPal, Block, other fintech stocks return to earth after COVID boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2208572369","media":"seekingalpha","summary":"After PayPal Holdings stock dives on weak 2022 guidance and a pivot in customer acquisition strategy","content":"<html><head></head><body><p>After <a href=\"https://laohu8.com/S/PYPL\">PayPal Holdings</a> stock dives on weak 2022 guidance and a pivot in customer acquisition strategy, against an overall weak backdrop for fintech stocks.</p><p>Fintech, online lending, and payment stocks turn down, extending a months-long slump in the sector as investors grow risk averse.</p><p>Note that <a href=\"https://laohu8.com/S/FINX\">Global X FinTech Thematic ETF</a> has dropped 30% in the past six months. <a href=\"https://laohu8.com/S/PYPL\">PayPal </a> fell 52%, <a href=\"https://laohu8.com/S/SQ\">Square </a> -58%, <a href=\"https://laohu8.com/S/LSPD\">Lightspeed Commerce </a> -61%, <a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies </a> -20%, and <a href=\"https://laohu8.com/S/UPST\">Upstart Holdings </a> -16% over the same timeframe.<img src=\"https://static.tigerbbs.com/7c1cfc4293939d79741a639fded127c6\" tg-width=\"852\" tg-height=\"581\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>In Wednesday trading, <a href=\"https://laohu8.com/S/SQ\">Block</a> drops after completing its acquisition of Afterpay. Other payment names dip as well: Paysafe (PSFE), Lightspeed Commerce (LSPD), Fiserv (FISV), and Global Payment (GPN).</p><p>Online lending names also suffer: Upstart Holdings (UPST), <a href=\"https://laohu8.com/S/LC\">LendingClub</a>, Blend Labs (BLND), <a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a>, and SoFi Technologies (SOFI). <a href=\"https://laohu8.com/S/TREE\">LendingTree</a> rises after its preliminary Q4 results topped consensus.</p><p>And while investors shy away from PayPal (PYPL) in a big way after the disappointing guidance, Mizuho analyst Dan Dolev sees some notable positives in its Q4 results — incremental total payment volume growth ex-eBay(EBAY)/P2P accelerated in Q4 to $55B from $53B in Q3 and the take rate (also ex-eBay) increased by 5 basis points, "marking a potential change in trend." He explains PayPal's recent weakness as a "return to earth" after a "COVID sugar rush" in 2020 and 2021.</p><p>"On balance, despite the understandable knee-jerk negative reaction, we see signs of the COVID hangover coming to an end, opening a new opportunity in PYPL," Dolev wrote in a note to clients.</p><p>Oppenheimer analyst Dominick Gabriele also sees PayPal's (PYPL) swoon as a buying opportunity. "After our post 3Q21 cautious stance we see significant upside on the kitchen-sink outlook/soured sentiment and we're going bottom fishing."</p><p>Raymond James analyst John Davis, though, isn't convinced. "PYPL is a 'show-me' story, and we believe the stock is unlikely to re-rate meaningfully higher before growth reaccelerates and investors gain confidence the 2022 outlook is overly conservative, which isn't likely to happen before 2H22," he wrote.</p><p>SA contributor Kirk Spano presents an option selling strategy for PayPal and Block</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PayPal, Block, other fintech stocks return to earth after COVID boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPayPal, Block, other fintech stocks return to earth after COVID boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 13:51 GMT+8 <a href=https://seekingalpha.com/news/3795036-paypal-block-other-fintech-stocks-return-to-earth-after-covid-boost><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After PayPal Holdings stock dives on weak 2022 guidance and a pivot in customer acquisition strategy, against an overall weak backdrop for fintech stocks.Fintech, online lending, and payment stocks ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795036-paypal-block-other-fintech-stocks-return-to-earth-after-covid-boost\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4106":"数据处理与外包服务","BK4566":"资本集团","BK4554":"元宇宙及AR概念","BK4503":"景林资产持仓","BK4524":"宅经济概念","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","BK4527":"明星科技股","PYPL":"PayPal","SQ":"Block","BK4534":"瑞士信贷持仓","BK4528":"SaaS概念"},"source_url":"https://seekingalpha.com/news/3795036-paypal-block-other-fintech-stocks-return-to-earth-after-covid-boost","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2208572369","content_text":"After PayPal Holdings stock dives on weak 2022 guidance and a pivot in customer acquisition strategy, against an overall weak backdrop for fintech stocks.Fintech, online lending, and payment stocks turn down, extending a months-long slump in the sector as investors grow risk averse.Note that Global X FinTech Thematic ETF has dropped 30% in the past six months. PayPal fell 52%, Square -58%, Lightspeed Commerce -61%, SoFi Technologies -20%, and Upstart Holdings -16% over the same timeframe.In Wednesday trading, Block drops after completing its acquisition of Afterpay. Other payment names dip as well: Paysafe (PSFE), Lightspeed Commerce (LSPD), Fiserv (FISV), and Global Payment (GPN).Online lending names also suffer: Upstart Holdings (UPST), LendingClub, Blend Labs (BLND), Rocket Companies, and SoFi Technologies (SOFI). LendingTree rises after its preliminary Q4 results topped consensus.And while investors shy away from PayPal (PYPL) in a big way after the disappointing guidance, Mizuho analyst Dan Dolev sees some notable positives in its Q4 results — incremental total payment volume growth ex-eBay(EBAY)/P2P accelerated in Q4 to $55B from $53B in Q3 and the take rate (also ex-eBay) increased by 5 basis points, \"marking a potential change in trend.\" He explains PayPal's recent weakness as a \"return to earth\" after a \"COVID sugar rush\" in 2020 and 2021.\"On balance, despite the understandable knee-jerk negative reaction, we see signs of the COVID hangover coming to an end, opening a new opportunity in PYPL,\" Dolev wrote in a note to clients.Oppenheimer analyst Dominick Gabriele also sees PayPal's (PYPL) swoon as a buying opportunity. \"After our post 3Q21 cautious stance we see significant upside on the kitchen-sink outlook/soured sentiment and we're going bottom fishing.\"Raymond James analyst John Davis, though, isn't convinced. \"PYPL is a 'show-me' story, and we believe the stock is unlikely to re-rate meaningfully higher before growth reaccelerates and investors gain confidence the 2022 outlook is overly conservative, which isn't likely to happen before 2H22,\" he wrote.SA contributor Kirk Spano presents an option selling strategy for PayPal and Block","news_type":1},"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091280330,"gmtCreate":1643872168124,"gmtModify":1676533866444,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280330","repostId":"1158451728","repostType":4,"repost":{"id":"1158451728","pubTimestamp":1643866207,"share":"https://www.laohu8.com/m/news/1158451728?lang=&edition=full","pubTime":"2022-02-03 13:30","market":"us","language":"en","title":"MetLife Q4 Profit Beats View","url":"https://stock-news.laohu8.com/highlight/detail?id=1158451728","media":"RTTNews","summary":"(RTTNews) - MetLife Inc. reported that its fourth quarter net income available to common shareholde","content":"<html><head></head><body><p>(RTTNews) - <a href=\"https://laohu8.com/S/MET\">MetLife Inc. </a> reported that its fourth quarter net income available to common shareholders climbed to $1.2 billion or $1.39 per share, from last year's $124 million or $0.14 per share, primarily driven by higher derivative losses in the prior-year period.</p><p>Adjusted earnings were $1.8 billion or $2.17 per share, compared to adjusted earnings of $1.8 billion or $2.03 per share in the fourth quarter of 2020.</p><p>Adjusted earnings, excluding total notable items, were $1.7 billion or $2.01 per share, compared to adjusted earnings, excluding total notable items, of $1.8 billion, or $2.03 per share, in the fourth quarter of 2020. Analysts polled by Thomson Reuters expected the company to report earnings of $1.47 per share for the fourth quarter. Analysts' estimates typically exclude special items.</p><p>Premiums, fees and other revenues was $15.2 billion, down 4 percent from the fourth quarter of 2020. Adjusted premiums, fees and other revenues were $15.0 billion, down 4 percent on a reported basis and 3 percent on a constant currency basis from the prior-year period.</p></body></html>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetLife Q4 Profit Beats View</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetLife Q4 Profit Beats View\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 13:30 GMT+8 <a href=https://www.nasdaq.com/articles/metlife-q4-profit-beats-view><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(RTTNews) - MetLife Inc. reported that its fourth quarter net income available to common shareholders climbed to $1.2 billion or $1.39 per share, from last year's $124 million or $0.14 per share, ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/metlife-q4-profit-beats-view\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MET":"大都会人寿"},"source_url":"https://www.nasdaq.com/articles/metlife-q4-profit-beats-view","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158451728","content_text":"(RTTNews) - MetLife Inc. reported that its fourth quarter net income available to common shareholders climbed to $1.2 billion or $1.39 per share, from last year's $124 million or $0.14 per share, primarily driven by higher derivative losses in the prior-year period.Adjusted earnings were $1.8 billion or $2.17 per share, compared to adjusted earnings of $1.8 billion or $2.03 per share in the fourth quarter of 2020.Adjusted earnings, excluding total notable items, were $1.7 billion or $2.01 per share, compared to adjusted earnings, excluding total notable items, of $1.8 billion, or $2.03 per share, in the fourth quarter of 2020. Analysts polled by Thomson Reuters expected the company to report earnings of $1.47 per share for the fourth quarter. Analysts' estimates typically exclude special items.Premiums, fees and other revenues was $15.2 billion, down 4 percent from the fourth quarter of 2020. Adjusted premiums, fees and other revenues were $15.0 billion, down 4 percent on a reported basis and 3 percent on a constant currency basis from the prior-year period.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9091280665,"gmtCreate":1643872246305,"gmtModify":1676533866452,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls thanks","listText":"Like pls thanks","text":"Like pls thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280665","repostId":"2208572369","repostType":4,"repost":{"id":"2208572369","pubTimestamp":1643867517,"share":"https://www.laohu8.com/m/news/2208572369?lang=&edition=full","pubTime":"2022-02-03 13:51","market":"us","language":"en","title":"PayPal, Block, other fintech stocks return to earth after COVID boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2208572369","media":"seekingalpha","summary":"After PayPal Holdings stock dives on weak 2022 guidance and a pivot in customer acquisition strategy","content":"<html><head></head><body><p>After <a href=\"https://laohu8.com/S/PYPL\">PayPal Holdings</a> stock dives on weak 2022 guidance and a pivot in customer acquisition strategy, against an overall weak backdrop for fintech stocks.</p><p>Fintech, online lending, and payment stocks turn down, extending a months-long slump in the sector as investors grow risk averse.</p><p>Note that <a href=\"https://laohu8.com/S/FINX\">Global X FinTech Thematic ETF</a> has dropped 30% in the past six months. <a href=\"https://laohu8.com/S/PYPL\">PayPal </a> fell 52%, <a href=\"https://laohu8.com/S/SQ\">Square </a> -58%, <a href=\"https://laohu8.com/S/LSPD\">Lightspeed Commerce </a> -61%, <a href=\"https://laohu8.com/S/SOFI\">SoFi Technologies </a> -20%, and <a href=\"https://laohu8.com/S/UPST\">Upstart Holdings </a> -16% over the same timeframe.<img src=\"https://static.tigerbbs.com/7c1cfc4293939d79741a639fded127c6\" tg-width=\"852\" tg-height=\"581\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>In Wednesday trading, <a href=\"https://laohu8.com/S/SQ\">Block</a> drops after completing its acquisition of Afterpay. Other payment names dip as well: Paysafe (PSFE), Lightspeed Commerce (LSPD), Fiserv (FISV), and Global Payment (GPN).</p><p>Online lending names also suffer: Upstart Holdings (UPST), <a href=\"https://laohu8.com/S/LC\">LendingClub</a>, Blend Labs (BLND), <a href=\"https://laohu8.com/S/RKT\">Rocket Companies</a>, and SoFi Technologies (SOFI). <a href=\"https://laohu8.com/S/TREE\">LendingTree</a> rises after its preliminary Q4 results topped consensus.</p><p>And while investors shy away from PayPal (PYPL) in a big way after the disappointing guidance, Mizuho analyst Dan Dolev sees some notable positives in its Q4 results — incremental total payment volume growth ex-eBay(EBAY)/P2P accelerated in Q4 to $55B from $53B in Q3 and the take rate (also ex-eBay) increased by 5 basis points, "marking a potential change in trend." He explains PayPal's recent weakness as a "return to earth" after a "COVID sugar rush" in 2020 and 2021.</p><p>"On balance, despite the understandable knee-jerk negative reaction, we see signs of the COVID hangover coming to an end, opening a new opportunity in PYPL," Dolev wrote in a note to clients.</p><p>Oppenheimer analyst Dominick Gabriele also sees PayPal's (PYPL) swoon as a buying opportunity. "After our post 3Q21 cautious stance we see significant upside on the kitchen-sink outlook/soured sentiment and we're going bottom fishing."</p><p>Raymond James analyst John Davis, though, isn't convinced. "PYPL is a 'show-me' story, and we believe the stock is unlikely to re-rate meaningfully higher before growth reaccelerates and investors gain confidence the 2022 outlook is overly conservative, which isn't likely to happen before 2H22," he wrote.</p><p>SA contributor Kirk Spano presents an option selling strategy for PayPal and Block</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PayPal, Block, other fintech stocks return to earth after COVID boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPayPal, Block, other fintech stocks return to earth after COVID boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 13:51 GMT+8 <a href=https://seekingalpha.com/news/3795036-paypal-block-other-fintech-stocks-return-to-earth-after-covid-boost><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After PayPal Holdings stock dives on weak 2022 guidance and a pivot in customer acquisition strategy, against an overall weak backdrop for fintech stocks.Fintech, online lending, and payment stocks ...</p>\n\n<a href=\"https://seekingalpha.com/news/3795036-paypal-block-other-fintech-stocks-return-to-earth-after-covid-boost\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4106":"数据处理与外包服务","BK4566":"资本集团","BK4554":"元宇宙及AR概念","BK4503":"景林资产持仓","BK4524":"宅经济概念","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","BK4527":"明星科技股","PYPL":"PayPal","SQ":"Block","BK4534":"瑞士信贷持仓","BK4528":"SaaS概念"},"source_url":"https://seekingalpha.com/news/3795036-paypal-block-other-fintech-stocks-return-to-earth-after-covid-boost","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2208572369","content_text":"After PayPal Holdings stock dives on weak 2022 guidance and a pivot in customer acquisition strategy, against an overall weak backdrop for fintech stocks.Fintech, online lending, and payment stocks turn down, extending a months-long slump in the sector as investors grow risk averse.Note that Global X FinTech Thematic ETF has dropped 30% in the past six months. PayPal fell 52%, Square -58%, Lightspeed Commerce -61%, SoFi Technologies -20%, and Upstart Holdings -16% over the same timeframe.In Wednesday trading, Block drops after completing its acquisition of Afterpay. Other payment names dip as well: Paysafe (PSFE), Lightspeed Commerce (LSPD), Fiserv (FISV), and Global Payment (GPN).Online lending names also suffer: Upstart Holdings (UPST), LendingClub, Blend Labs (BLND), Rocket Companies, and SoFi Technologies (SOFI). LendingTree rises after its preliminary Q4 results topped consensus.And while investors shy away from PayPal (PYPL) in a big way after the disappointing guidance, Mizuho analyst Dan Dolev sees some notable positives in its Q4 results — incremental total payment volume growth ex-eBay(EBAY)/P2P accelerated in Q4 to $55B from $53B in Q3 and the take rate (also ex-eBay) increased by 5 basis points, \"marking a potential change in trend.\" He explains PayPal's recent weakness as a \"return to earth\" after a \"COVID sugar rush\" in 2020 and 2021.\"On balance, despite the understandable knee-jerk negative reaction, we see signs of the COVID hangover coming to an end, opening a new opportunity in PYPL,\" Dolev wrote in a note to clients.Oppenheimer analyst Dominick Gabriele also sees PayPal's (PYPL) swoon as a buying opportunity. \"After our post 3Q21 cautious stance we see significant upside on the kitchen-sink outlook/soured sentiment and we're going bottom fishing.\"Raymond James analyst John Davis, though, isn't convinced. \"PYPL is a 'show-me' story, and we believe the stock is unlikely to re-rate meaningfully higher before growth reaccelerates and investors gain confidence the 2022 outlook is overly conservative, which isn't likely to happen before 2H22,\" he wrote.SA contributor Kirk Spano presents an option selling strategy for PayPal and Block","news_type":1},"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098877231,"gmtCreate":1644109434122,"gmtModify":1676533890164,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098877231","repostId":"2209346488","repostType":4,"repost":{"id":"2209346488","pubTimestamp":1644030901,"share":"https://www.laohu8.com/m/news/2209346488?lang=&edition=full","pubTime":"2022-02-05 11:15","market":"us","language":"en","title":"Big Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2209346488","media":"Bloomberg","summary":"This week was one for the record books for big tech, in ways both good and historically bad.Results ","content":"<html><head></head><body><p>This week was one for the record books for big tech, in ways both good and historically bad.</p><p>Results from a trio of Wall Street’s most widely followed names spurred huge weekly moves, with hundreds of billions of dollars getting created or evaporated. For Alphabet Inc. and Amazon.com Inc., strong reports underlined their growth prospects, spurring rallies that led to their biggest one-week percentage gains in months. For <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a>, the Facebook parent that had the single-worst day in Wall Street history by one metric, it was a different story.</p><p>Alphabet rose 7.5% for the week, its best such performance since October. Earlier this week, it reported results that beat expectations, help by a robust performance in its advertising business. The week’s advance added $122.5 billion to its market valuation, bringing it close to the $2 trillion threshold. It rose 0.1% on Friday.</p><p>Amazon rose 9.5% for the week, its biggest one-week gain since July 2020. The bulk of the week’s advance came on Friday, when shares surged nearly 14% on the back of a report that also sailed past expectations. Friday’s move was the biggest percentage gain for the stock since April 2015, and the nearly $191 billion it added in market value was a record one-day value gain for the U.S. market.</p><p>On the other end of the scale, Meta fell 21% over the week, its biggest one-week drop on record. The collapse came after it gave a weak revenue forecast amid stagnating user growth and increasing competition from TikTok. Shares suffered their biggest drop ever on Thursday, resulting in the biggest one-day wipeout of market value for any U.S. company in history. The stock fell 0.3% on Friday.</p><p>Overall, the tech-heavy Nasdaq 100 Index rose 1.7% for the week, its second straight weekly gain. Last week it was supported by strong reports from other mega-cap stocks, including Apple Inc. and Microsoft.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Big Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBig Tech’s Week Featured Alphabet and Amazon Rallies, Meta Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-05 11:15 GMT+8 <a href=https://finance.yahoo.com/news/big-tech-week-featured-alphabet-212244501.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This week was one for the record books for big tech, in ways both good and historically bad.Results from a trio of Wall Street’s most widely followed names spurred huge weekly moves, with hundreds of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/big-tech-week-featured-alphabet-212244501.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4553":"喜马拉雅资本持仓","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","GOOG":"谷歌","BK4525":"远程办公概念","BK4566":"资本集团","AMZN":"亚马逊","BK4535":"淡马锡持仓","BK4524":"宅经济概念","BK4508":"社交媒体","BK4527":"明星科技股","BK4538":"云计算","BK4559":"巴菲特持仓","BK4077":"互动媒体与服务","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4122":"互联网与直销零售","BK4551":"寇图资本持仓","AAPL":"苹果","BK4561":"索罗斯持仓","BK4548":"巴美列捷福持仓","MSFT":"微软","GOOGL":"谷歌A"},"source_url":"https://finance.yahoo.com/news/big-tech-week-featured-alphabet-212244501.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2209346488","content_text":"This week was one for the record books for big tech, in ways both good and historically bad.Results from a trio of Wall Street’s most widely followed names spurred huge weekly moves, with hundreds of billions of dollars getting created or evaporated. For Alphabet Inc. and Amazon.com Inc., strong reports underlined their growth prospects, spurring rallies that led to their biggest one-week percentage gains in months. For Meta Platforms, the Facebook parent that had the single-worst day in Wall Street history by one metric, it was a different story.Alphabet rose 7.5% for the week, its best such performance since October. Earlier this week, it reported results that beat expectations, help by a robust performance in its advertising business. The week’s advance added $122.5 billion to its market valuation, bringing it close to the $2 trillion threshold. It rose 0.1% on Friday.Amazon rose 9.5% for the week, its biggest one-week gain since July 2020. The bulk of the week’s advance came on Friday, when shares surged nearly 14% on the back of a report that also sailed past expectations. Friday’s move was the biggest percentage gain for the stock since April 2015, and the nearly $191 billion it added in market value was a record one-day value gain for the U.S. market.On the other end of the scale, Meta fell 21% over the week, its biggest one-week drop on record. The collapse came after it gave a weak revenue forecast amid stagnating user growth and increasing competition from TikTok. Shares suffered their biggest drop ever on Thursday, resulting in the biggest one-day wipeout of market value for any U.S. company in history. The stock fell 0.3% on Friday.Overall, the tech-heavy Nasdaq 100 Index rose 1.7% for the week, its second straight weekly gain. Last week it was supported by strong reports from other mega-cap stocks, including Apple Inc. and Microsoft.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091280276,"gmtCreate":1643872269422,"gmtModify":1676533866453,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like pls thanks","listText":"Like pls thanks","text":"Like pls thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280276","repostId":"1196109622","repostType":4,"repost":{"id":"1196109622","pubTimestamp":1643852105,"share":"https://www.laohu8.com/m/news/1196109622?lang=&edition=full","pubTime":"2022-02-03 09:35","market":"us","language":"en","title":"2 Biotech Stocks That Could Make You Richer","url":"https://stock-news.laohu8.com/highlight/detail?id=1196109622","media":"Motley Fool","summary":"Investing in the stock market won't make you rich overnight. But with a patient approach to investin","content":"<html><head></head><body><p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.</p><p>Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a> and <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a>. Here's why.</p><p>1. <a href=\"https://laohu8.com/S/BLUE\"><b>Bluebird Bio</b></a></p><p>To say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.</p><p>On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.</p><p>However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called<b>2Seventy Bio</b>.</p><p>Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.</p><p>There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.</p><p>The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).</p><p>ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.</p><p>Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.</p><p>However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.</p><p>2. <a href=\"https://laohu8.com/S/EXEL\"><b>Exelixis</b></a></p><p>Exelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.</p><p>Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.</p><p>First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.</p><p>Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.</p><p>The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.</p><p>Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Biotech Stocks That Could Make You Richer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Biotech Stocks That Could Make You Richer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 09:35 GMT+8 <a href=https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXEL":"伊克力西斯","BLUE":"bluebird bio Inc."},"source_url":"https://www.fool.com/investing/2022/02/02/2-biotech-stocks-that-could-make-you-richer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196109622","content_text":"Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time.Let's address the second part of this strategy: picking the right stocks, which isn't always an easy task. If you need some inspiration, here are two biotech stocks that are currently down and out with investors -- and while they carry some risk, I believe they have the potential to deliver strong returns to the patient shareholder: Bluebird Bio and Exelixis. Here's why.1. Bluebird BioTo say that Bluebird Bio has lagged the market in the past year would be an understatement. The gene-editing specialist has lost over 70% of its value in the trailing-12-month period, a horrible performance by any metric. The company owes this poor showing to a combination of factors, but as is usual with biotech companies, clinical and regulatory setbacks played a significant role.On the positive side, Bluebird has proven that it can earn regulatory nods for multiple therapies -- few other gene-editing companies can say the same. Both Skysona, a treatment for a pediatric neurodegenerative disorder called cerebral adrenoleukodystrophy (CALD), and Zynteglo, a therapy for the blood disorder transfusion-dependent beta-thalassemia (TDT), were approved in Europe.However, the company opted to leave the European market after failing to land a good deal with third-party payers for its approved gene-editing treatments. It also has had to pause a couple of clinical trials because of suspected adverse reactions. And it recently spun off its oncology business into a separate entity called2Seventy Bio.Where does that leave Bluebird? It leaves the biotech with a pipeline focused on rare illnesses and some promising programs on the way. In September, the company submitted an application to the U.S. Food and Drug Administration for beti-cel, a treatment for TDT that was branded as Zynteglo in Europe.There are few treatments for TDT. But Bluebird's version of the therapy that was approved in Europe costs a hefty 1.58 million euros. The biotech will almost certainly set a high price in the U.S. as well if beti-cel gets approved. There is no denying the value it would bring to patients: a one-time, curative treatment for a disorder that would otherwise require regular blood transfusions for survival.The company has also submitted a U.S. application for eli-cel, a treatment for CALD that was approved in Europe this past December as Skysona. The FDA granted eli-cel priority review, which is reserved for therapies that could be an improvement over existing treatments. CALD is the most severe form of adrenoleukodystrophy (ALD).ALD itself is pretty rare, and 40% of boys diagnosed with it end up developing CALD. The only known treatment for this illness is a stem-cell transplant. Eli-cel and beti-cel could both be approved this year with the potential to generate at least several hundred million dollars in peak annual sales -- if not significantly more.Bluebird looks a bit on the risky side. It currently has no products on the market and is consistently unprofitable. And the biotech could run into even more regulatory headwinds, which would sink its stock even further.However, Bluebird's current market cap is barely over $500 million. The market isn't putting much value in the company's programs at all. That's what makes this biotech a potentially attractive option. If the company's master plan actualizes, its shares could skyrocket.2. ExelixisExelixis is best-known for its cancer medicine Cabometyx, approved for renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). In fact, it represents the bulk of the company's sales. But thebiotech's reliance on its crown jewel doesn't bode well for many investors, which partly explains why the company has lagged the market -- down some 18% over the past year.Still, there is hope for Exelixis, which will report its full financial results on Feb. 17.First, Cabometyx has continued to increase its sales while grinding out more indications. Exelixis recently announced preliminary results for last year. For the fourth quarter, it expects an 11.1% year-over-year increase in revenue to $300 million -- a solid performance. For the full year, it's estimating $1.08 billion in revenue, an increase of 9.4%. And for 2022, it's predicting $1.3 billion to $1.4 billion in revenue.Cabometyx is also still being tested in dozens of clinical trials. Results from several phase 3 studies should come in this year, so the cancer medicine could once again earn label expansions. That's good news for Exelixis and its shareholders.The biotech is now looking to replicate the success it's had with Cabometyx. It's advancing several pipeline candidates through early-stage clinical trials, including a trio of cancer therapies: XL092, XL102, and XB002. The company will update investors on the progress of these programs this year, and these updates could help send its stock price higher.Within the next couple of years, these products should be moving into late-stage studies. Exelixis' forward price-to-earnings ratio of about 15 -- while higher than the industry average of 11 -- is about as low as it has been in over two years. In the long run, Exelixis should rebound from its recent woes, and it might be worth adding shares of the company right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9091280330,"gmtCreate":1643872168124,"gmtModify":1676533866444,"author":{"id":"4106832071804060","authorId":"4106832071804060","name":"78887480","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091280330","repostId":"1158451728","repostType":4,"repost":{"id":"1158451728","pubTimestamp":1643866207,"share":"https://www.laohu8.com/m/news/1158451728?lang=&edition=full","pubTime":"2022-02-03 13:30","market":"us","language":"en","title":"MetLife Q4 Profit Beats View","url":"https://stock-news.laohu8.com/highlight/detail?id=1158451728","media":"RTTNews","summary":"(RTTNews) - MetLife Inc. reported that its fourth quarter net income available to common shareholde","content":"<html><head></head><body><p>(RTTNews) - <a href=\"https://laohu8.com/S/MET\">MetLife Inc. </a> reported that its fourth quarter net income available to common shareholders climbed to $1.2 billion or $1.39 per share, from last year's $124 million or $0.14 per share, primarily driven by higher derivative losses in the prior-year period.</p><p>Adjusted earnings were $1.8 billion or $2.17 per share, compared to adjusted earnings of $1.8 billion or $2.03 per share in the fourth quarter of 2020.</p><p>Adjusted earnings, excluding total notable items, were $1.7 billion or $2.01 per share, compared to adjusted earnings, excluding total notable items, of $1.8 billion, or $2.03 per share, in the fourth quarter of 2020. Analysts polled by Thomson Reuters expected the company to report earnings of $1.47 per share for the fourth quarter. Analysts' estimates typically exclude special items.</p><p>Premiums, fees and other revenues was $15.2 billion, down 4 percent from the fourth quarter of 2020. Adjusted premiums, fees and other revenues were $15.0 billion, down 4 percent on a reported basis and 3 percent on a constant currency basis from the prior-year period.</p></body></html>","source":"lsy1603171495471","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetLife Q4 Profit Beats View</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetLife Q4 Profit Beats View\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-03 13:30 GMT+8 <a href=https://www.nasdaq.com/articles/metlife-q4-profit-beats-view><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(RTTNews) - MetLife Inc. reported that its fourth quarter net income available to common shareholders climbed to $1.2 billion or $1.39 per share, from last year's $124 million or $0.14 per share, ...</p>\n\n<a href=\"https://www.nasdaq.com/articles/metlife-q4-profit-beats-view\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MET":"大都会人寿"},"source_url":"https://www.nasdaq.com/articles/metlife-q4-profit-beats-view","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158451728","content_text":"(RTTNews) - MetLife Inc. reported that its fourth quarter net income available to common shareholders climbed to $1.2 billion or $1.39 per share, from last year's $124 million or $0.14 per share, primarily driven by higher derivative losses in the prior-year period.Adjusted earnings were $1.8 billion or $2.17 per share, compared to adjusted earnings of $1.8 billion or $2.03 per share in the fourth quarter of 2020.Adjusted earnings, excluding total notable items, were $1.7 billion or $2.01 per share, compared to adjusted earnings, excluding total notable items, of $1.8 billion, or $2.03 per share, in the fourth quarter of 2020. Analysts polled by Thomson Reuters expected the company to report earnings of $1.47 per share for the fourth quarter. Analysts' estimates typically exclude special items.Premiums, fees and other revenues was $15.2 billion, down 4 percent from the fourth quarter of 2020. Adjusted premiums, fees and other revenues were $15.0 billion, down 4 percent on a reported basis and 3 percent on a constant currency basis from the prior-year period.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
